Figure 9.

Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced cold allodynia following drug removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-induced protection against paclitaxel-induced cold allodynia was not blocked by either a CB1 (AM251, 3 mg/kg/day s.c.) or CB2 (AM630, 3 mg/kg/day s.c.) antagonist. b. Protective anti-allodynic effects associated with AM1710 (3.2 mg/kg/day s.c.) were mediated via CB2 receptor activation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Taxol-Vehicle, +P < 0.05, ++P < 0.01 vs. Taxol-Agonist + AM630 (3), xP < 0.05, xxP < 0.01, Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, P < 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle ϕP < 0.05, ϕϕϕP < 0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ^^P < 0.01 Taxol-Agonist and Taxol-Agonist + AM630 (3) vs. Taxol-Vehicle, αP < 0.05 Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Cremophor-Vehicle. All doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 6–8 per group.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27
Download authors' original image